Literature DB >> 6402143

Identification of adverse reactions to new drugs. IV--Verification of suspected adverse reactions.

G R Venning.   

Abstract

The verification processes were assessed for 18 important adverse drug reactions. Verification when achieved by formal studies was not obtained through cohort studies such as postmarketing surveillance or other follow up of drug users but through case-control studies or a similar disease orientated approach. When not achieved in this way the most useful aspects of uncontrolled studies were rechallenge and dose-response data. Analysis of the data and of the characteristics of different methods of verification suggested that there were four approaches to earlier discovery. (1) The best system seemed to be some form of record linkage, capable of providing at the same time data on incidence of adverse reactions and on prevalence of drug usage in patients with disease suspected of being drug induced. Until such a system can be established the relative efficacy of alternative approaches appears to be (2) review of all published first alerts, with prompt initiation of case-control or disease orientated studies for verification, (3) postmarketing surveillance of cohorts of drug users, and (4) voluntary reporting systems.

Entities:  

Mesh:

Year:  1983        PMID: 6402143      PMCID: PMC1546579          DOI: 10.1136/bmj.286.6364.544

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  9 in total

1.  Facial paralysis.

Authors:  H Miller
Journal:  Br Med J       Date:  1967-09-30

2.  Epidemic incidence of Bell's palsy.

Authors:  U Leibowitz
Journal:  Brain       Date:  1969-03       Impact factor: 13.501

3.  The discovery of drug-induced illness.

Authors:  H Jick
Journal:  N Engl J Med       Date:  1977-03-03       Impact factor: 91.245

4.  Identification of adverse reactions to new drugs. II--How were 18 important adverse reactions discovered and with what delays?

Authors:  G R Venning
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-22

5.  Identification of adverse reactions to new drugs. II (continued): How were 18 important adverse reactions discovered and with what delays?

Authors:  G R Venning
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-29

6.  Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide?

Authors:  G R Venning
Journal:  Br Med J (Clin Res Ed)       Date:  1983-01-15

7.  Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems.

Authors:  G R Venning
Journal:  Br Med J (Clin Res Ed)       Date:  1983-02-05

8.  Postmarketing follow-up.

Authors:  H Jick; A M Walker; C Spriet-Pourra
Journal:  JAMA       Date:  1979-11-23       Impact factor: 56.272

9.  Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs.

Authors:  W H Inman; M P Vessey; B Westerholm; A Engelund
Journal:  Br Med J       Date:  1970-04-25
  9 in total
  10 in total

Review 1.  Antipsychotic-induced venous thromboembolism: a review of the evidence.

Authors:  Staffan Hägg; Olav Spigset
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 2.  Pharmaco-epidemiological perspectives.

Authors:  U Bergman
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

3.  Signal detection: historical background.

Authors:  Toine C G Egberts
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  Improving adverse drug reaction monitoring.

Authors:  J McEwen
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Nov-Dec

5.  Development of recommendations for the protection of short-stay travellers to malaria endemic areas: Memorandum from two WHO Meetings.

Authors: 
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

6.  Postmarketing surveillance of adverse drug reactions: problems and solutions.

Authors:  F M Lortie
Journal:  CMAJ       Date:  1986-07-01       Impact factor: 8.262

Review 7.  Rare and serious adverse reactions.

Authors:  G R Venning
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

8.  Malaria chemoprophylaxis among European tourists in tropical Africa: use, adverse reactions, and efficacy.

Authors:  R Steffen; R Heusser; R Mächler; R Bruppacher; U Naef; D Chen; A M Hofmann; B Somaini
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

9.  Sources of information on lymphoma associated with anti-tumour necrosis factor agents: comparison of published case reports and cases reported to the French pharmacovigilance system.

Authors:  Hélène Théophile; Thierry Schaeverbeke; Ghada Miremont-Salamé; Abdelilah Abouelfath; Valentine Kahn; Françoise Haramburu; Bernard Bégaud
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

Review 10.  Does proof of casualty ever exist in pharmacovigilance?

Authors:  M Auriche; E Loupi
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.